Recorded at Kite Pharma, Santa Monica, CA
Kite Pharma’s eminent statistician, Lynn Navale, examines challenges and solutions in determining historical control estimations so common in early, single arm oncology studies. Without accurate control, trial planners risk mistakenly declaring futility if control is too high or if too low, wasting resources pursuing treatment with no compelling efficacy.
At Cytel, we believe that expert statistical input increases the probability of clinical trial success. Our consulting statisticians support a range of issues from complex adaptive trial designs, to product development program strategy. All the leading pharmaceutical, biotech and medical devices companies use Cytel’s software for clinical trial design, analysis and implementation.
Learn more at cytel.com